Puma Biotechnology (NYSE:PBYI) presents at ASCO thepositive results from an ongoing Phase II clinical trial of Puma's investigational drug PB272 for the treatment of HER2-positive metastatic breast cancer that has metastasized to the brain. <\/p>\n
The multicenter Phase II clinical trial enrolled patients with HER2-positive metastatic breast cancer who have brain metastases. The trial is being performed by the TBCRC and enrolled three cohorts of patients. <\/p>\n
We are very pleased with the activity seen in this trial with the combination of neratinib plus capecitabine, sys Puma CEOAlan Auerbach. <\/p>\n
As a small molecule that can cross the blood brain barrier, neratinib potentially offers patients with HER2-positive metastatic breast cancer that has metastasized to the CNS a novel HER2 targeted treatment option. We look forward to working with TBCRC on future trials of neratinib in patients with HER2-positive disease metastatic to the CNS,\" he adds. <\/p>\n
Source: Press Release <\/p>\n
#ASCO <\/p>\n
<\/p>\n
Read more here: Puma Biotechnology (NYSE:PBYI) presents at ASCO thepositive results from an ongoing Phase II clinical trial of Puma's investigational drug PB272 for the treatment of HER2-positive metastatic breast cancer that has metastasized to the brain. The multicenter Phase II clinical trial enrolled patients with HER2-positive metastatic breast cancer who have brain metastases. Continue reading
\nPuma Biotechnology announces positive trial results - Seeking Alpha<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"